erlotinib hydrochloride has been researched along with batimastat in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (batimastat) | Trials (batimastat) | Recent Studies (post-2010) (batimastat) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 347 | 6 | 56 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | batimastat (IC50) |
|---|---|---|---|
| 5-hydroxytryptamine receptor 3E | Homo sapiens (human) | 0.025 | |
| 5-hydroxytryptamine receptor 3B | Homo sapiens (human) | 0.025 | |
| Interstitial collagenase | Homo sapiens (human) | 0.3158 | |
| Low affinity immunoglobulin epsilon Fc receptor | Homo sapiens (human) | 0.1 | |
| 72 kDa type IV collagenase | Homo sapiens (human) | 0.3029 | |
| Stromelysin-1 | Homo sapiens (human) | 1.1205 | |
| Matrilysin | Homo sapiens (human) | 3.5012 | |
| Matrix metalloproteinase-9 | Homo sapiens (human) | 0.0066 | |
| Neutrophil collagenase | Homo sapiens (human) | 0.7 | |
| Metabotropic glutamate receptor 5 | Rattus norvegicus (Norway rat) | 1.2 | |
| Collagenase 3 | Homo sapiens (human) | 0.005 | |
| 5-hydroxytryptamine receptor 3A | Homo sapiens (human) | 0.025 | |
| Matrix metalloproteinase-14 | Homo sapiens (human) | 0.5715 | |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | 0.0149 | |
| Snake venom metalloproteinase BaP1 | Bothrops asper (terciopelo) | 1.2 | |
| 5-hydroxytryptamine receptor 3D | Homo sapiens (human) | 0.025 | |
| 5-hydroxytryptamine receptor 3C | Homo sapiens (human) | 0.025 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armstrong, C; Durkin, AJ; Osborne, DA; Rosemurgy, AS; Yeatman, TJ; Zervos, EE | 1 |
1 other study(ies) available for erlotinib hydrochloride and batimastat
| Article | Year |
|---|---|
EGF receptor antagonism improves survival in a murine model of pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Animals; Cell Division; Cell Line, Tumor; Disease Models, Animal; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression; Humans; Mice; Mice, Nude; Pancreatic Neoplasms; Phenylalanine; Protease Inhibitors; Protein Kinase Inhibitors; Quinazolines; Survival Rate; Thiophenes | 2006 |